Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERBB2 | P04626 | 15/20 | 0.85 |
| ▸ | EGFR | P00533 | 14/20 | 0.85 |
| ▸ | LCK | P06239 | 1/20 | 0.70 |
| ▸ | KDR | P35968 | 1/20 | 0.70 |
| ▸ | AAK1 | Q2M2I8 | 5/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1219493 | 0.92 | EGFR (1.00) | ERBB2EGFRLCKKDRAAK1 | |
| SCHEMBL1219763 | 0.92 | ERBB2 (1.00) | ERBB2EGFRLCKKDRAAK1 | |
| SCHEMBL1218777 | 0.89 | ERBB2 (0.80) | ERBB2EGFRLCKKDRAAK1 | |
| SCHEMBL1219592 | 0.89 | ERBB2 (1.00) | ERBB2EGFRLCKKDRAAK1 | |
| SCHEMBL1218552 | 0.89 | ERBB2 (0.84) | ERBB2EGFRLCKKDRAAK1 | |
| SCHEMBL1219685 | 0.88 | EGFR (0.74) | ERBB2EGFRLCKKDRAAK1 | |
| SCHEMBL1219490 | 0.87 | ERBB2 (1.00) | ERBB2EGFRLCKKDRAAK1 | |
| SCHEMBL3553531 | 0.87 | EGFR (0.81) | ERBB2EGFRLCKKDRAAK1 | |
| SCHEMBL1220086 | 0.86 | EGFR (0.77) | ERBB2EGFRLCKKDRAAK1 | |
| SCHEMBL1219772 | 0.86 | ERBB2 (0.77) | ERBB2EGFRLCKKDRAAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110039838-A1 | PYRROLOTRIAZINE COMPOUNDS AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2011-02-17 | — | — | US | disclosed |
| US-7846931-B2 | Pyrrolotriazine compounds as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-12-07 | — | — | US | disclosed |
| EP-1699797-B1 | PYRROLOTRIAZINE COMPOUNDS AS KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2009-09-23 | — | — | EP | disclosed |
| EP-2058314-A1 | Pyrrolotriazine compounds as kinase inhibitors | Bristol-Myers Squibb Company (US) | 2009-05-13 | — | — | EP | disclosed |
| US-20090048244-A1 | PYRROLOTRIAZINE COMPOUNDS AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2009-02-19 | — | — | US | disclosed |
| US-7297695-B2 | Pyrrolotriazine compounds as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-11-20 | — | — | US | disclosed |
| US-7141571-B2 | Pyrrolotriazine compounds as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-11-28 | — | — | US | disclosed |
| US-20060264438-A1 | PYRROLOTRIAZINE COMPOUNDS AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-11-23 | — | — | US | disclosed |
| US-20050182058-A1 | Pyrrolotriazine compounds as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2005-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110039838-A1 | PYRROLOTRIAZINE COMPOUNDS AS KINASE INHIBITORS | ERBB2, ERBB4, ERBB3 | ERBB2 1/4885EGFR 4/4885LCK 21/4885 |
| US-20060264438-A1 | PYRROLOTRIAZINE COMPOUNDS AS KINASE INHIBITORS | ERBB2, ERBB4, ERBB3 | ERBB2 1/4885EGFR 4/4885LCK 21/4885 |
| US-20050182058-A1 | Pyrrolotriazine compounds as kinase inhibitors | ERBB2, ERBB4, ERBB3 | ERBB2 1/4885EGFR 4/4885LCK 21/4885 |
| US-20090048244-A1 | PYRROLOTRIAZINE COMPOUNDS AS KINASE INHIBITORS | ERBB2, ERBB4, ERBB3 | ERBB2 1/4885EGFR 4/4885LCK 21/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.